PubMed · 9327999
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A M Thierry, S Pirot, Y Gioanni, J Glowinski. 1998. Dopamine function in the prefrontal cortex.. https://doi.org/10.1016/s1054-3589(08)60848-0
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The differentiation of striatal GABAergic neurons coincides with the perinatal establishment of nigrostriatal dopaminergic synaptic connections. We have shown previously that dopamine stimulates the maturation of striatal GABAergic neurons. Since BDNF also regulates the development of GABAergic cells, we hypothesized that dopamine might affect striatal BDNF expression. The influence of dopamine on BDNF protein/mRNA and trkB mRNA levels was studied in neuronal and astroglia cultures of the mouse striatum. Stimulation with dopamine and a dopamine D1 receptor agonist increased BDNF mRNA and protein but not trkB mRNA in neuronal cultures. Our data indicate a potential role for dopamine in the developmental regulation of striatal BDNF expression and suggest that dopamine effects on GABAergic cells may be intertwined with BDNF action.
Muscarinic acetylcholine receptors (M1-M5) play important roles in the modulation of many key functions of the central and peripheral nervous system. To explore the physiological roles of the two Gi-coupled muscarinic receptors, we disrupted the M2 and M4 receptor genes in mice by using a gene targeting strategy. Pharmacological and behavioral analysis of the resulting mutant mice showed that the M2 receptor subtype is critically involved in mediating three of the most striking central muscarinic effects, tremor, hypothermia, and analgesia. These studies also indicated that M4 receptors are not critically involved in these central muscarinic responses. However, M4 receptor-deficient mice showed an increase in basal locomotor activity and greatly enhanced locomotor responses following drug-induced activation of D1 dopamine receptors. This observation is consistent with the concept that M4 receptors exert inhibitory control over D1 receptor-mediated locomotor stimulation, probably at the level of striatal projection neurons where the two receptors are known to be coexpressed. These findings emphasize the usefulness of gene targeting approaches to shed light on the physiological and pathophysiological roles of the individual muscarinic receptor subtypes.
The present study explored the role of dopaminergic transmission in spinal cord in a model of carrageenan-induced inflammatory pain by examining the effects of selective agonists and antagonists of dopamine receptors. The results were as follows: (1) trans-(-)-4aR-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo[3,4-g] quinoline hydrochloride (LY171555), a dopamine D(2) receptor agonist, produced anti-hyperalgesia (150 and 300 nmol) or hypoalgesia (300 nmol) in the inflamed hindpaws and non-inflamed hindpaws, respectively; spiperone hydrochloride (8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one hydrochloride), a dopamine D(2) receptor antagonist, decreased the pain threshold of non-inflamed hindpaws (300 nmol). (2) (+/-)-SKF38393 hydrochloride ((+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride), a dopamine D(1) receptor agonist, had no effect on either hindpaw, even at a higher dose (300 nmol); R(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (R(+)-SCH23390 hydrochloride), a dopamine D(1) receptor antagonist, induced anti-hyperalgesia in the inflamed hindpaws (300 nmol). The present results suggest that the dopaminergic system in the spinal cord is involved in the central modulation of inflammatory hyperalgesia, and that the different effects are probably induced by different receptors.